<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763450</url>
  </required_header>
  <id_info>
    <org_study_id>Avastin Study</org_study_id>
    <nct_id>NCT01763450</nct_id>
  </id_info>
  <brief_title>Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer</brief_title>
  <official_title>LIAONING CANCER HOSPITAL&amp;INSTITUTE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liaoning Tumor Hospital &amp; Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, non-random, open study ,to observe efficacy and safety of bevacizumab plus
      Oxaliplatin based multidrug chemotherapy as conversion therapy for patients with previously
      untreated unresectable liver metastases from colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES：To assess the objective response rate(ORR)（8 weeks after chemotherapy）

      SECONDARY OBJECTIVES：

        1. To assess the R0 resection rate of liver metastases（8 weeks after chemotherapy、every
           three months follow-up 1 time in R0 postoperative 1-2 years、Every six months follow-up 1
           time in R0 postoperative 2-5 years）

        2. To assess the incidence of adverse events of level 3-4 （Bleeding、Gastrointestinal
           Perforation、Anastomotic Fistula、Hypertension、Wound Healing Delay）（8 weeks after
           chemotherapy）
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the objective response rate(ORR)</measure>
    <time_frame>8 weeks after chemotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the R0 resection rate of liver metastases</measure>
    <time_frame>8 weeks after chemotherapy、every three months follow-up 1 time in R0 postoperative 1-2 years、Every six months follow-up 1 time in R0 postoperative 2-5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the incidence of adverse events of level 3-4 （Bleeding、Gastrointestinal Perforation、Anastomotic Fistula、Hypertension、Wound Healing Delay）</measure>
    <time_frame>8 weeks after chemotherapy</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Metastases</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab:
7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;
Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;
Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:
Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab plus chemotherapy</intervention_name>
    <description>Bevacizumab:
7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;
Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;
Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:
Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;</description>
    <arm_group_label>Bevacizumab plus chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written inform consent form

          2. histologically or cytologically confirmed Colorectal Adenocarcinoma

          3. Age≥18 and ≤80 years old

          4. Primary colorectal cancer and liver metastases，Liver lesions determined to be
             unresectable by multidisciplinary team (MDT) （primary lesions surgically removed）

          5. Simultaneity or heterochrony metastases

          6. Colorectal cancer lesions from anal edge at least 8 cm

          7. Within 6 months did not receive any chemotherapy, including targeted therapy

          8. One or more measurable lesions, conventional Computed Tomography(CT) scanning
             measurement diameter at least 20 mm [Response Evaluation Criteria In Solid
             Tumors(RECIST) standard]

          9. Eastern Collaborative Oncology Group(ECOG) 0 or 1

         10. Expected lifetime at least for 12 weeks

         11. Screening within 7 days， the ability of bone marrow, liver and kidney function reserve
             enough；Absolute neutrophil count（ANC）≥1.5x109/L; hemoglobin≥9.0g/dl; platelet count≥80
             x109/L; Total Bilirubin(TBil)≤1.5 x upper level of normal range(ULN); Alanine
             Aminotransferase(ALT) and Aspartate Aminotransferase(AST)≤2.5 x ULN(Patients with
             hepatic metastasis≤5x ULN); alkaline phosphatase≤4 x ULN; serum creatinine≤1.5 x ULN;

         12. Women of reproductive age should take effective contraceptive measures;

        Exclusion Criteria:

          1. Arrhythmia requiring medication（except β- receptor blocking pharmacon and
             digoxigenin），symptomatic coronary artery disease and myocardial ischemia [myocardial
             infarction (≤6months before enrollment)]，congestive heart failure [≥New York Heart
             Association(NYHA)2];

          2. History of HIV infection,Chronic hepatitis B or hepatitis C of active phase(high copy
             virus DNA);

          3. Other activated serious infection [&gt;National Cancer Institute-Common Toxicity
             Criteria(NCI-CTC) 3.0];

          4. Any extrahepatic metastases;

          5. Seizures requiring medication(such as steroids or antiepileptic therapy);

          6. Other malignancies in the past 5 years (except curatively treated basal cell carcinoma
             of the skin and/or in situ carcinoma of the cervix);

          7. Chronic inflammatory bowel disease, intestinal obstruction;

          8. Drug abuse and medicine, psychology or social conditions may interfere with patients
             to participate in research or the results of the evaluation have influence;

          9. Known or suspected allergy to any investigational drug in this study;

         10. Any unstable condition or is likely to endanger the patient safety and compliance
             situation;

         11. Pregnant or lactating women not using or refusing to use effective non hormonal means
             of contraception;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun Song, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Second Affiliated Hosptial of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150086</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital&amp;Institute</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2012</study_first_submitted>
  <study_first_submitted_qc>January 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2013</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Liaoning Tumor Hospital &amp; Institute</investigator_affiliation>
    <investigator_full_name>Chun Song</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bevacizumab</keyword>
  <keyword>conversion therapy</keyword>
  <keyword>liver metastases</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>objective response rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

